Zhongyuan Cui, Xia Lei, Yani Gou, Zhixian Wu, Xiaojun Huang
{"title":"OCIAD2作为一种新的胰腺癌预后和治疗生物标志物：基于转录组特征和生物信息学分析的研究","authors":"Zhongyuan Cui, Xia Lei, Yani Gou, Zhixian Wu, Xiaojun Huang","doi":"10.1371/journal.pcbi.1013566","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It is urgent to explore the potential biomarkers for pancreatic cancer (PC) prognosis and treatment to improve patients' outcomes.</p><p><strong>Methods: </strong>Firstly, we performed an integrated bioinformatics analysis based on extensive transcriptome data from 615 PC tumors and 329 adjacent tissues, screening for genes with prognostic value. We then validated the prognostic value of OCIAD2, DCBLD2, and SAMD9 in different datasets and analyzed their expression levels in single-cell sequencing datasets of normal, paracancer, primary, and metastatic tissues. Next, we further explored the carcinogenic effect after knocking down the expression of OCIAD2 in PC cancer cell line. Finally, a drug sensitivity analysis was conducted.</p><p><strong>Results: </strong>Differentially expressed genes (DEGs) analysis identified 22 DEGs: ACSL5, ANTXR1, AP1S3, ATP2C2, B3GNT5, C15orf48, CAPG, CTSK, DAPP1, DCBLD2, GPX8, HEPH, IFI44, KRT23, NCF2, OCIAD2, SAMD9, SLC39A10, ST6GALNAC1, TBC1D2, TMSB10 and TSPAN5 with prognostic value in PC, though the related function and mechanism are still unclear. Single-cell sequencing results indicated that OCIAD2 was prominently expressed in ductal cells of primary and metastatic tumors. The expression levels of OCIAD2 mRNA and protein were the highest in pancreatic tumor tissues. Mechanism studies revealed that STAT1 and STAT2 in the JAK-STAT pathway and CCND1, CDK1, and CDK2 in the cell cycle pathway were significantly down-regulated after OCIAD2 knockdown. Drug sensitivity analysis identified 25 compounds significantly associated with OCIAD2.</p><p><strong>Conclusions: </strong>These results indicate that OCIAD2 is a potential prognostic biomarker and therapeutic target for PC patients.</p>","PeriodicalId":20241,"journal":{"name":"PLoS Computational Biology","volume":"21 10","pages":"e1013566"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517509/pdf/","citationCount":"0","resultStr":"{\"title\":\"OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis.\",\"authors\":\"Zhongyuan Cui, Xia Lei, Yani Gou, Zhixian Wu, Xiaojun Huang\",\"doi\":\"10.1371/journal.pcbi.1013566\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>It is urgent to explore the potential biomarkers for pancreatic cancer (PC) prognosis and treatment to improve patients' outcomes.</p><p><strong>Methods: </strong>Firstly, we performed an integrated bioinformatics analysis based on extensive transcriptome data from 615 PC tumors and 329 adjacent tissues, screening for genes with prognostic value. We then validated the prognostic value of OCIAD2, DCBLD2, and SAMD9 in different datasets and analyzed their expression levels in single-cell sequencing datasets of normal, paracancer, primary, and metastatic tissues. Next, we further explored the carcinogenic effect after knocking down the expression of OCIAD2 in PC cancer cell line. Finally, a drug sensitivity analysis was conducted.</p><p><strong>Results: </strong>Differentially expressed genes (DEGs) analysis identified 22 DEGs: ACSL5, ANTXR1, AP1S3, ATP2C2, B3GNT5, C15orf48, CAPG, CTSK, DAPP1, DCBLD2, GPX8, HEPH, IFI44, KRT23, NCF2, OCIAD2, SAMD9, SLC39A10, ST6GALNAC1, TBC1D2, TMSB10 and TSPAN5 with prognostic value in PC, though the related function and mechanism are still unclear. Single-cell sequencing results indicated that OCIAD2 was prominently expressed in ductal cells of primary and metastatic tumors. The expression levels of OCIAD2 mRNA and protein were the highest in pancreatic tumor tissues. Mechanism studies revealed that STAT1 and STAT2 in the JAK-STAT pathway and CCND1, CDK1, and CDK2 in the cell cycle pathway were significantly down-regulated after OCIAD2 knockdown. Drug sensitivity analysis identified 25 compounds significantly associated with OCIAD2.</p><p><strong>Conclusions: </strong>These results indicate that OCIAD2 is a potential prognostic biomarker and therapeutic target for PC patients.</p>\",\"PeriodicalId\":20241,\"journal\":{\"name\":\"PLoS Computational Biology\",\"volume\":\"21 10\",\"pages\":\"e1013566\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-10-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517509/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS Computational Biology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pcbi.1013566\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS Computational Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1371/journal.pcbi.1013566","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis.
Background: It is urgent to explore the potential biomarkers for pancreatic cancer (PC) prognosis and treatment to improve patients' outcomes.
Methods: Firstly, we performed an integrated bioinformatics analysis based on extensive transcriptome data from 615 PC tumors and 329 adjacent tissues, screening for genes with prognostic value. We then validated the prognostic value of OCIAD2, DCBLD2, and SAMD9 in different datasets and analyzed their expression levels in single-cell sequencing datasets of normal, paracancer, primary, and metastatic tissues. Next, we further explored the carcinogenic effect after knocking down the expression of OCIAD2 in PC cancer cell line. Finally, a drug sensitivity analysis was conducted.
Results: Differentially expressed genes (DEGs) analysis identified 22 DEGs: ACSL5, ANTXR1, AP1S3, ATP2C2, B3GNT5, C15orf48, CAPG, CTSK, DAPP1, DCBLD2, GPX8, HEPH, IFI44, KRT23, NCF2, OCIAD2, SAMD9, SLC39A10, ST6GALNAC1, TBC1D2, TMSB10 and TSPAN5 with prognostic value in PC, though the related function and mechanism are still unclear. Single-cell sequencing results indicated that OCIAD2 was prominently expressed in ductal cells of primary and metastatic tumors. The expression levels of OCIAD2 mRNA and protein were the highest in pancreatic tumor tissues. Mechanism studies revealed that STAT1 and STAT2 in the JAK-STAT pathway and CCND1, CDK1, and CDK2 in the cell cycle pathway were significantly down-regulated after OCIAD2 knockdown. Drug sensitivity analysis identified 25 compounds significantly associated with OCIAD2.
Conclusions: These results indicate that OCIAD2 is a potential prognostic biomarker and therapeutic target for PC patients.
期刊介绍：
PLOS Computational Biology features works of exceptional significance that further our understanding of living systems at all scales—from molecules and cells, to patient populations and ecosystems—through the application of computational methods. Readers include life and computational scientists, who can take the important findings presented here to the next level of discovery.
Research articles must be declared as belonging to a relevant section. More information about the sections can be found in the submission guidelines.
Research articles should model aspects of biological systems, demonstrate both methodological and scientific novelty, and provide profound new biological insights.
Generally, reliability and significance of biological discovery through computation should be validated and enriched by experimental studies. Inclusion of experimental validation is not required for publication, but should be referenced where possible. Inclusion of experimental validation of a modest biological discovery through computation does not render a manuscript suitable for PLOS Computational Biology.
Research articles specifically designated as Methods papers should describe outstanding methods of exceptional importance that have been shown, or have the promise to provide new biological insights. The method must already be widely adopted, or have the promise of wide adoption by a broad community of users. Enhancements to existing published methods will only be considered if those enhancements bring exceptional new capabilities.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
